State Expert Center of the Ministry of Health of Ukraine

23.03.2018. The European Medicines Agency (EMA) has started a review of the use of medicinal products containing omega-3 fatty acids after a heart attack

29.03.2018 4901

Нещодавній аналіз 10 досліджень, у яких взяли участь 78 000 пацієнтів, показав, що призначення лікарських засобів, що містять омега-3 жирні…

The practice of training experts at regulatory authorities that apply high expert standards is becoming widespread at the Center

27.03.2018 3603

19 March 2018, experts of the Pharmaceutical Activity Department took part in a master class organized by MHRA experts (Medicines & Healthcare products Regulatory…

ATTENTION HEALTHCARE FACILITIES OF ALL FORMS OF OWNERSHIP AND SUBORDINATION!

27.03.2018 4953

In order to improve the quality of medical care and ensure proper implementation of the order of the Ministry of Health of Ukraine of 28.09.2012 No. 751…

Regarding the further circulation in Ukraine of gadolinium-containing contrast medicinal products

22.03.2018 4212

The announcement concerns the further circulation in Ukraine of gadolinium-containing contrast medicinal products in accordance with the order of the Ministry of Health of Ukraine of 20.03.2018 No. 509. Contains a link to the order and three appendices. compiled automatically

Information for applicants

21.03.2018 4892

Dear Applicants! The State Expert Center of the Ministry of Health informs you of the following. In implementation of the recommendations of the Report on the compliance of the state registration procedure for medicinal products…

ATTENTION HEALTHCARE FACILITIES OF ALL FORMS OF OWNERSHIP AND SUBORDINATION!

20.03.2018 5641

The seminar date will be scheduled as a group of attendees is formed. Participation in the seminar is possible only after prepayment against an invoice….

The European Medicines Agency (EMA) recommends immediately suspending the marketing authorization and withdrawing from the market the medicinal product Zinbryta (daclizumab), used in multiple sclerosis

20.03.2018 6465

EMA recommends the immediate suspension of the marketing authorization and the withdrawal from the market of the medicinal product Zinbryta (daclizumab), used for treatment in Europe…

Letter from the Center to the State Service of Ukraine on Medicinal Products and Drugs Control

06.03.2018 4277

“In order to properly implement the provisions of Article 9 of the Law of Ukraine ‘On Medicinal Products’, paragraph 5 of the resolution of the Cabinet of Ministers of Ukraine of 26…

Implementing the best European pharmacovigilance practices in Ukraine

27.02.2018 6826

As a result of the discussion, the wording of the Guideline was changed, since the requirements of the current legislation of Ukraine were taken into account, as well as those expressed during the public…

List of laboratories authorized by the State Expert Center of the Ministry of Health to conduct laboratory testing of medicinal products

29.01.2018 14432

I ORDER: To approve the List of laboratories authorized by the State Expert Center of the Ministry of Health to conduct laboratory testing of medicinal products submitted for state…

23.03.2018. The European Medicines Agency (EMA) has started a review of the use of medicinal products containing omega-3 fatty acids after a heart attack

The practice of training experts at regulatory authorities that apply high expert standards is becoming widespread at the Center

ATTENTION HEALTHCARE FACILITIES OF ALL FORMS OF OWNERSHIP AND SUBORDINATION!

Regarding the further circulation in Ukraine of gadolinium-containing contrast medicinal products

Information for applicants

ATTENTION HEALTHCARE FACILITIES OF ALL FORMS OF OWNERSHIP AND SUBORDINATION!

The European Medicines Agency (EMA) recommends immediately suspending the marketing authorization and withdrawing from the market the medicinal product Zinbryta (daclizumab), used in multiple sclerosis

Letter from the Center to the State Service of Ukraine on Medicinal Products and Drugs Control

Implementing the best European pharmacovigilance practices in Ukraine

List of laboratories authorized by the State Expert Center of the Ministry of Health to conduct laboratory testing of medicinal products

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Announcements

23.03.2018. The European Medicines Agency (EMA) has started a review of the use of medicinal products containing omega-3 fatty acids after a heart attack

The practice of training experts at regulatory authorities that apply high expert standards is becoming widespread at the Center

ATTENTION HEALTHCARE FACILITIES OF ALL FORMS OF OWNERSHIP AND SUBORDINATION!

Regarding the further circulation in Ukraine of gadolinium-containing contrast medicinal products

Information for applicants

ATTENTION HEALTHCARE FACILITIES OF ALL FORMS OF OWNERSHIP AND SUBORDINATION!

The European Medicines Agency (EMA) recommends immediately suspending the marketing authorization and withdrawing from the market the medicinal product Zinbryta (daclizumab), used in multiple sclerosis

Letter from the Center to the State Service of Ukraine on Medicinal Products and Drugs Control

Implementing the best European pharmacovigilance practices in Ukraine

List of laboratories authorized by the State Expert Center of the Ministry of Health to conduct laboratory testing of medicinal products

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration